Roche is pleased to introduce a new and highly potent bisphosphanate for the treatment of postmenopausal osteoporosis. Bonviva (Ibandronic Acid) 150mg tablet is the first and only once-monthly tablet that provides bisphosphonate efficacy in a convenient once-monthly dosing with a proven tolerability profile.
Various clinical trial have reported the efficacy and safety of Bonviva including the pivotal BONE trial. In this study Bonviva was shown to significantly reduce the risk of new morphometric vertebral fractures by 62% and to increase bone mineral density(BMD) as early as 6 months. In addition, a non-vertebral fracture risk reduction of 69% was observed in a subgroup of patients at high risk of fracture. Studies have also demonstrated that Bonviva increases bone strength in OVER 9 OUT OF 10 women, maximizing their chance of treatment success.
As with all long-term osteoporosis medication, treatment works best when patients are committed to staying on therapy. Let your pharmacists to share with you how Bonviva can offer patients an alternative convenient regimen, providing the link to enhanced adherence and improved treatment outcomes.
1 comment:
Hello. This post is likeable, and your blog is very interesting, congratulations :-). I will add in my blogroll =). If possible gives a last there on my blog, it is about the Impressora e Multifuncional, I hope you enjoy. The address is http://impressora-multifuncional.blogspot.com. A hug.
Post a Comment